PRLog - July 25, 2012 - MINNEAPOLIS -- Since the development of new drugs can be time consuming and expensive, drug repositioning has emerged as a potentially cost-effective and quicker alternative to provide new drugs for pharmaceutical companies’ waning pipelines. Approved drugs have already met with the FDA’s approval therefore, the early stages of drug development can be bypassed. By mining existing drugs for new uses, researchers can focus instead on the clinical testing portion of the process. This shortens the development timeline and gets new treatments to patients faster. With new technologies and approaches, drug repositioning has become more streamlined and less accidental than it was in the past. By using a more systematic approach, existing compounds are being tested for both common and neglected diseases faster and with more success.
Drug Repositioning banner
The 2nd Annual Drug Repositioning Conference to be held on October 23-24, 2012 in San Francisco, CA will feature a variety of speakers from academia, industry, non-profits and government.
David Cipolla, Senior Director of Pharma Sciences at Aradigm Corporation, will present on “Repositioning Drugs using Formulation and Delivery Technology.”
Steve Jenner, VP Marketing at Zogenix, Inc., will present on “Repositioning an Underutilized Gold-standard Treatment by Leveraging Novel Delivery Technology: A Case Study of Sumavel®DosPro®
Please visit http://www.drugrepositioningconference.com for a preliminary agenda and information on how to register to attend.